$ENTX

Entera Bio (ENTX): Longitude entities report 4.6% ownership, Seven Fleet 4.1%

Entera Bio Ltd. (ENTX) disclosed in an SEC Schedule 13G that Longitude Venture Partners V, L.P. (via Longitude Capital Partners V, LLC and its managing members) is the record holder of 7,843,138 ordinary shares, or 4.6% of 172,251,411 shares outstanding as of July 28, 2026. The filing also references Seven Fleet’s potential 4.1% beneficial ownership.

Original reporting
Published Aug 5, 2026, 8:46 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 2:21 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefFinancial news
Primary signal
$ENTX
Neutral
medium confidence
Mentioned
$ENTX
Relevance
4/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$ENTXNeutralLow
01

Why it matters

The primary new information is the disclosed stake size (4.6% for Longitude entities) and the potential additional stake attribution (4.1% for Seven Fleet), which may affect ownership concentration and monitoring by other investors.

02

Market read

Traders may reassess ownership concentration and potential governance influence, but the filing provides no operational or strategic catalyst.

03

What to watch

The filing includes group-status and beneficial-ownership disclaimers; without evidence of activism, board influence may be less than traders assume.

Relevance 4/10Novelty 5/10Timing: today’s premarket ownership-disclosure read-through

Background

The text summarizes a Schedule 13G filing under the Exchange Act, detailing record and potential beneficial ownership for Entera Bio ordinary shares.

Company-level read

Ticker impact

$ENTXNeutralMedium confidence
Context

Entera Bio discloses a Schedule 13G showing Longitude Venture Partners V as record owner of 7,843,138 shares, 4.6% of the class.

Expected impact

Likely limited near-term price impact; any move would be sentiment-driven around ownership concentration rather than fundamentals.

Evidence & confidence

The article is a Schedule 13G ownership update (4.6% holder) with no accompanying deal, financing, or governance action described.

Market effects

For small-cap biotech, ownership concentration disclosures can affect perceived governance risk, but this filing alone does not change sector fundamentals.

None indicated.

None indicated.

Counterpoint

A 13G can reflect passive investment rather than activism, so the market may overreact to the headline ownership percentages.

Key entities

  • Entera Bio Ltd.

    Subject of the Schedule 13G ownership disclosure summarized in the article.

  • Longitude Venture Partners V, L.P.

    Record holder of 7,843,138 ordinary shares, reported as 4.6% of the class.

  • Longitude Capital Partners V, LLC

    General partner of the record holder, potentially sharing voting and dispositive power.

  • Seven Fleet

    May be deemed to beneficially own 7,053,898 ordinary shares, or 4.1%, under stated policies.

Related articles

$ENTXMedAI 8/10

Entera Bio to present Phase 3 trial design for oral osteoporosis drug

Entera Bio (ENTX) will present Phase 3 trial design for its oral osteoporosis drug, EB613, at a conference in October 2026. The study will evaluate EB613 in postmenopausal women with osteoporosis. The company previously reported positive Phase 2 results, showing improvements in bone density and markers. EB613 is an oral, once-daily tablet, unlike current anabolic therapies that require injections.

$ENTXMed

Entera Receives $9 Price Target and New 'Outperform' Rating From Leerink Partners (NASDAQ: ENTX)

Entera Bio (ENTX) received an 'Outperform' rating and $9 price target from Leerink Partners. The company's lead drug, EB613, is in development for osteoporosis and has completed Phase 2 trials. Entera recently raised $275M in funding and plans to initiate Phase 3 trials in late 2026, with data expected in 2028. ENTX was trading at $3.03 per share as of September 17, 2026.

$ENTXMedAI 8/10

Entera Bio Q2 EPS misses estimate as net loss widens to $7.3 million

Entera Bio Ltd. (NASDAQ: ENTX) reported Q2 2026 EPS loss of $0.14 versus a $0.08 consensus estimate, with net loss widening to $7.3 million from $2.7 million a year earlier, driven mainly by a $2.7 million non-cash warrant fair value remeasurement. The company also closed an oversubscribed $275 million private placement to fund EB613 Phase 3 NDA work through 2030.

$ENTXMedAI 8/10

Entera Announces Second Quarter 2026 Financial Results and Business Updates

Entera Bio Ltd. (ENTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Entera Announces Second Quarter 2026 Financial Results and Business Updates U.S. Food and Drug Administration (FDA) Alignment on 12-Month Registrational Phase 3 Study to Support NDA for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women wi